Pyrrolamide DNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening To Identify Antibacterial Agents - Wikidata - awgldk - TriplyDB

Pyrrolamide DNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening To Identify Antibacterial Agents

Pyrrolamide DNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening To Identify Antibacterial Agents

http://www.wikidata.org/entity/Q27676314

about

Optimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship and In Vivo Efficacy in a Mouse Model of Tuberculosis Fragment-Based Discovery of 6-Azaindazoles As Inhibitors of Bacterial DNA Ligase Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents Recent contributions of structure-based drug design to the development of antibacterial compounds.A novel high-throughput cell-based assay aimed at identifying inhibitors of DNA metabolism in bacteria Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.Discovery of ATP-Competitive Inhibitors of tRNAIle Lysidine Synthetase (TilS) by High-Throughput Screening.Biological evaluation and molecular modelling study of thiosemicarbazide derivatives as bacterial type IIA topoisomerases inhibitors.Hot-spot identification on a broad class of proteins and RNA suggest unifying principles of molecular recognition.Thermodynamic computational approach to capture molecular recognition in the binding of different inhibitors to the DNA gyrase B subunit from Escherichia coli.Design, synthesis, and biological evaluation of 1-ethyl-3-(thiazol-2-yl)urea derivatives as Escherichia coli DNA gyrase inhibitors.Synthesis and Evaluation of N-Phenylpyrrolamides as DNA Gyrase B Inhibitors.Design, Synthesis, and Evaluation of Novel Tyrosine-Based DNA Gyrase B Inhibitors.Assays, surrogates, and alternative technologies for a TB lead identification program targeting DNA gyrase ATPase.

P2860

Q27680342-4B602C59-321D-45BD-A0FC-43BA99D55300 Q27684181-57ACA937-EFC6-4CB2-A98F-280FE2318840 Q28538023-8EC4C7E5-4C36-47B8-96A4-3E79F71F4B20 Q30380194-0CF740B3-23B5-4EC1-9632-C4C0D31E192F Q30410098-EC9D64A6-390D-42A9-ADB5-D44650BF38BB Q34394167-874E3AB3-8846-47F3-BC12-43BE174BE3B9 Q35167286-61964229-3E37-46E2-B484-2B7D4488B124 Q38897223-0E9B2D3F-70B0-40D9-B016-06E63D9FA618 Q41512122-16DB1554-9364-41F4-A279-3E2930476B2F Q45717201-3660F2BD-CC31-4F96-9AA2-111EE1948A8B Q48120268-960F5667-2F1B-47A7-94CD-0E266652C9A4 Q48175813-19EBEF06-3387-4E0D-800D-220814ED0CC0 Q48266288-260859F2-9847-4C4A-9BA3-D9C401A18AF0 Q51027070-1AF3D3B1-97F3-43B7-85B3-A8BA831A45B6

P2860

Pyrrolamide DNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening To Identify Antibacterial Agents

http://www.wikidata.org/entity/Q27676314

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Pyrrolamide DNA Gyrase Inhibit ...... Identify Antibacterial Agents

@ast

Pyrrolamide DNA Gyrase Inhibit ...... Identify Antibacterial Agents

@en

Pyrrolamide DNA Gyrase Inhibit ...... Identify Antibacterial Agents

@en-gb

Pyrrolamide DNA Gyrase Inhibit ...... Identify Antibacterial Agents

@nl

type

label

Pyrrolamide DNA Gyrase Inhibit ...... Identify Antibacterial Agents

@ast

Pyrrolamide DNA Gyrase Inhibit ...... Identify Antibacterial Agents

@en

Pyrrolamide DNA Gyrase Inhibit ...... Identify Antibacterial Agents

@en-gb

Pyrrolamide DNA Gyrase Inhibit ...... Identify Antibacterial Agents

@nl

prefLabel

Pyrrolamide DNA Gyrase Inhibit ...... Identify Antibacterial Agents

@ast

Pyrrolamide DNA Gyrase Inhibit ...... Identify Antibacterial Agents

@en

Pyrrolamide DNA Gyrase Inhibit ...... Identify Antibacterial Agents

@en-gb

Pyrrolamide DNA Gyrase Inhibit ...... Identify Antibacterial Agents

@nl

P1433

Q27676314-C7099AA6-7A3C-4375-8DAC-D86A3072BF85

P1476

Q27676314-702860AC-0BB5-4AAD-A70B-332FE3C420E2

P2093

Q27676314-00F9A43A-80DF-4837-8F41-F409BEEB7E8C

Q27676314-0296542C-369B-4146-97CA-81E9A35BE3E4

Q27676314-110DE274-3B84-4C3C-88F5-43A22126BF60

Q27676314-130738A3-9F04-47E5-89A2-9FA45BFB83B2

Q27676314-13B28873-044F-4C33-830E-956FCBD78670

Q27676314-162007C1-B90F-4EE5-8FE8-3A38139830CF

Q27676314-1A6E369C-4B6A-4E85-B701-36015A6ABB14

Q27676314-3618A920-D785-4A41-B17E-A8F2B6880432

Q27676314-5287E1C7-D3EE-426F-BAE9-EF3ECE145186

Q27676314-55A836BE-A33B-45E3-832A-068A123C8BE4

P2860

Q27676314-0548B723-3224-46A3-8760-F0AB4C90B83C

Q27676314-08DB09F5-A164-4449-A621-D6F92F658A17

Q27676314-1099518B-5997-4539-BB97-55997EE85193

Q27676314-1416D541-037F-4BAE-8294-8EE30379DAC4

Q27676314-1FF7585B-4CA9-41DC-80AC-6CC7F303B620

Q27676314-2DB62423-453D-4AB7-B1B0-1EA35EC3A3A4

Q27676314-2FDEBA34-A9C7-427D-AEF4-D49EDF510DBD

Q27676314-3B5E2774-C2C5-4AA9-BEBC-1A1FA69E2F93

Q27676314-55FE720C-3B9B-49AE-BEF9-86E9DBBAA370

Q27676314-7E093905-C8B4-4F7A-AC0C-CE8BB0B831C0

P304

Q27676314-E6F56F55-1A88-4265-B5BD-B310425934DC

P31

Q27676314-4AAD25C8-FF2F-4FBA-A6C5-AD1D7D5094A4

P356

Q27676314-B66B532E-D7C2-4CAD-AD29-D9C30D5EBD5F

P407

Q27676314-FEC7EE0E-45BB-4B4F-AB02-5A4E7908F3C4

P433

Q27676314-C0A189AB-6403-417B-9DE3-980624EC70C7

P478

Q27676314-23DC0002-233F-4EDF-A35E-403BE9036C0A

P50

Q27676314-F2784635-AB6A-4D47-B95F-9A67A466C5A7

P577

Q27676314-FFEE82BE-53A6-4E04-937A-9639372837E7

P5875

Q27676314-41D6E083-1791-435F-8675-37FF905B438F

P698

Q27676314-8C3A0EB0-35BD-4812-9FF2-1B18BA76E5E2

P932

Q27676314-FC0E47F5-63EE-4324-9148-233A8C840DD9

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pyrrolamide DNA Gyrase Inhibit ...... Identify Antibacterial Agents

@en

P2093

Alok Singh

http://www.w3.org/2001/XMLSchema#string

Ann E Eakin

http://www.w3.org/2001/XMLSchema#string

April Blodgett

http://www.w3.org/2001/XMLSchema#string

Beth Andrews

http://www.w3.org/2001/XMLSchema#string

Brian Sherer

http://www.w3.org/2001/XMLSchema#string

Bryan Prince

http://www.w3.org/2001/XMLSchema#string

Dave Timms

http://www.w3.org/2001/XMLSchema#string

George Mullen

http://www.w3.org/2001/XMLSchema#string

Grant K Walkup

http://www.w3.org/2001/XMLSchema#string

Haihong Ni

http://www.w3.org/2001/XMLSchema#string

P2860

The ATP-binding site of type II topoisomerases as a target for antibacterial drugs

Drugs for bad bugs: confronting the challenges of antibacterial discovery

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

Ligand efficiency: a useful metric for lead selection

Discovering high-affinity ligands for proteins: SAR by NMR

An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes.

Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location.

In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model

Crystal structure of an N-terminal fragment of the DNA gyrase B protein.

Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli.

P304

1240-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.05485-11

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51901473

http://www.w3.org/2001/XMLSchema#string

P698

22183167

http://www.w3.org/2001/XMLSchema#string

P932

3294908

http://www.w3.org/2001/XMLSchema#string